113 related articles for article (PubMed ID: 12579979)
1. [Study on brain targeting 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine pharmacosomes].
Zhang ZR; Wang JX
Yao Xue Xue Bao; 2001 Oct; 36(10):771-6. PubMed ID: 12579979
[TBL] [Abstract][Full Text] [Related]
2. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles.
Wang JX; Sun X; Zhang ZR
Eur J Pharm Biopharm; 2002 Nov; 54(3):285-90. PubMed ID: 12445558
[TBL] [Abstract][Full Text] [Related]
3. [Optimization of the preparation of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine pharmacosomes using central composite design].
Zhang ZR; Wang JX; Lu J
Yao Xue Xue Bao; 2001 Jun; 36(6):456-61. PubMed ID: 12585133
[TBL] [Abstract][Full Text] [Related]
4. [Preparation and liver targeting of floxuridinyl dibutyrate solid lipid nanoparticles].
Li JJ; Yang GD; Wang HY; Zhang SQ
Yao Xue Xue Bao; 2008 Jul; 43(7):761-5. PubMed ID: 18819483
[TBL] [Abstract][Full Text] [Related]
5. In vivo distribution and antitumour activity of liposomal 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine.
Van Borssum Waalkes M; Fichtner I; Dontje B; Lemm M; Becker M; Arndt D; Scherphof GL
J Microencapsul; 1992; 9(3):335-46. PubMed ID: 1403484
[TBL] [Abstract][Full Text] [Related]
6. Conjugation of 5-fluoro-2'-deoxyuridine with lactosaminated poly-l-lysine to reduce extrahepatic toxicity in the treatment of hepatocarcinomas.
Di Stefano G; Busi C; Derenzini M; Trerè D; Fiume L
Ital J Gastroenterol Hepatol; 1998 Apr; 30(2):173-7. PubMed ID: 9675653
[TBL] [Abstract][Full Text] [Related]
7. The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes.
Supersaxo A; Rubas W; Hartmann HR; Schott H; Hengartner H; Schwendener RA
J Microencapsul; 1988; 5(1):1-11. PubMed ID: 2974073
[TBL] [Abstract][Full Text] [Related]
8. Toxicity of liposomal 3'-5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in mice.
van Borssum Waalkes M; Goris H; Dontje BH; Schwendener RA; Scherphof G; Nijhof W
Anticancer Drug Des; 1998 Jun; 13(4):291-305. PubMed ID: 9627669
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activity of O-alkyl-3-N-aminoacyloxymethyl-5-fluoro-2'-deoxyuridine derivatives.
Harada N; Hongu M; Kawaguchi T; Ohohashi M; Oda K; Hashiyama T; Tsujihara K
Chem Pharm Bull (Tokyo); 1996 Jun; 44(6):1196-201. PubMed ID: 8814951
[TBL] [Abstract][Full Text] [Related]
10. Nonlinear elimination kinetics of 5-fluoro-2'-deoxyuridine in isolated perfused rat liver and isolated hepatocytes.
Foth H; Kunellis EM; Müseler T; Kahl GF
J Pharmacol Exp Ther; 1990 Aug; 254(2):427-32. PubMed ID: 2143535
[TBL] [Abstract][Full Text] [Related]
11. Organ distribution of 5-fluorouracil loaded gelatine microspheres in mice.
Hao X; Cheng G; Zou M; Sun J; Cui F
Pharmazie; 2004 Sep; 59(9):709-12. PubMed ID: 15497754
[TBL] [Abstract][Full Text] [Related]
12. Comparison of intraperitoneal continuous infusion of floxuridine and bolus administration in a peritoneal gastric cancer xenograft model.
Inoue K; Onishi H; Kato Y; Michiura T; Nakai K; Sato M; Yamamichi K; Machida Y; Nakane Y
Cancer Chemother Pharmacol; 2004 May; 53(5):415-22. PubMed ID: 15132129
[TBL] [Abstract][Full Text] [Related]
13. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
Gao K; Jiang X
Int J Pharm; 2006 Mar; 310(1-2):213-9. PubMed ID: 16426779
[TBL] [Abstract][Full Text] [Related]
14. [Preparation of lung targeting azithromycin liposomes and its tissue distribution in mice].
Wang JS; Zhu JB; Lu RQ; Shen W
Yao Xue Xue Bao; 2005 Mar; 40(3):274-8. PubMed ID: 15952603
[TBL] [Abstract][Full Text] [Related]
15. In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives.
van Borssum Waalkes M; van Galen M; Morselt H; Sternberg B; Scherphof GL
Biochim Biophys Acta; 1993 May; 1148(1):161-72. PubMed ID: 8499464
[TBL] [Abstract][Full Text] [Related]
16. Selective accumulation of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine (FdUrd-C8) and sustained release of its active metabolites in VX-2 rabbit hepatoma following intraarterial administration of FdUrd-C8 solution in Lipiodol.
Kawaguchi T; Fukushima S; Hayashi Y; Kaneko M; Nakano M
Cancer Res; 1988 Aug; 48(15):4179-83. PubMed ID: 2839289
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes.
Zhu L; Huo Z; Wang L; Tong X; Xiao Y; Ni K
Int J Pharm; 2009 Mar; 370(1-2):136-43. PubMed ID: 19114095
[TBL] [Abstract][Full Text] [Related]
18. Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes.
Koning GA; Kamps JA; Scherphof GL
Cancer Detect Prev; 2002; 26(4):299-307. PubMed ID: 12430634
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and properties of 5-fluorouracil oligonucleotides.
Koga M; Yasusa T; Yamamoto M; Haba S; Suzuki T; Saeki T; Ozaki S
Nucleic Acids Symp Ser; 1995; (34):27-8. PubMed ID: 8841535
[TBL] [Abstract][Full Text] [Related]
20. Controlled release of 5-fluoro-2'-deoxyuridine by the combination of prodrug and polymer matrix.
Endoh H; Kawaguchi T; Seki T; Hasegawa T; Juni K
Chem Pharm Bull (Tokyo); 1991 Feb; 39(2):458-64. PubMed ID: 1829027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
